専門医のための精神科臨床リュミエール25　向精神薬のリスク・ベネフィット

出版社： 中山書店
著者：
発行日： 2011-05-20
分野： 臨床医学：内科  >  精神医学
ISBN： 9784521732428
シリーズ： 専門医のための精神科臨床リュミエール
電子書籍版： 2011-05-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

8,580 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

8,580 円(税込)

購入する

商品紹介

本書では、「向精神薬50年の歩み」「薬物療法の到達点」「薬物治療と他の治療法との比較」「向精神薬の未来」の４章により、向精神薬の作用機序の発見に至る経緯、各精神疾患の薬物療法が到達しえた技法やトピックス、薬物療法が新たに生み出した問題や未来への展望について、第一線の臨床家に、最新の知見を開陳していただいた。精緻な精神科薬物療法の決定版である。

目次

  • 専門医のための精神科臨床リュミエール25　
    向精神薬のリスク・ベネフィット

    ―目次―

    I　向精神薬50年の歩み
    　1．抗精神病薬：antipsychotic drug
    　2．抗うつ薬
    　3．抗不安薬・睡眠薬

    II　薬物療法の到達点
    　A. 統合失調症
    　B. 大うつ病性障害
    　C. 双極性障害
    　D．不安障害

    III　薬物治療と他の治療法との比較

    IV　向精神薬の未来

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 向精神薬 50 年の歩み

P.16 掲載の参考文献
1) 八木剛平, 田辺英. 精神病治療の開発思想史-ネオヒポクラティズムの系譜. 東京 : 星和書店 ; 1999.
 
2) Cannon WB. Wisdom of the Body. / 舘鄰, 舘澄江 (訳). からだの知恵-この不思議なはたらき. 東京 : 講談社 ; 1981.
 
3) Selye H. The Stress of Life. McGraw-Hill ; 1978. / 杉靖三郎ほか (訳). 現代社会とストレス. 東京 : 法政大学出版局 ; 1988.
 
4) 柴田整一. 抗生物質普及の果たした意外な側面-内因性疾患時代の幕開け. 日本医事新報 1981 ; 2980 : 13-16.
 
5) Laborit H. Reaction organique a l'agression et choc. 山口与一ほか (訳). 侵襲に対する生体反応とショック-人工冬眠療法の原理と応用. 大阪 : 最新医学社 ; 1956.
 
6) 八木剛平. 現代精神医学定説批判-ネオヒポクラティズムの眺望. 東京 : 金原出版 ; 2005.
 
7) Delay J, Deniker P. Methodes chimiotherapiques en psychiatrie. Paris : Masson et Cie ; 1963. / 秋元波留夫ほか (訳). 臨床精神薬理学. 東京 : 紀伊國屋書店 ; 1965. p353.
 
8) 八木剛平, 伊藤斉. 抗精神病薬 (neuroleptics) による錐体外路症状-その治療的意義の変遷について. 精神医学 1983 ; 25 : 452-466, 570-582, 686-701.
 
9) 八木剛平, 渡邊衡一郎, 高野晴成. 初発分裂病に対する治療薬の選択と用量について. 精神神経誌1999 ; 101 : 908-915.
 
10) Zubin J. 精神分裂病の「一時発症, episode」の原因における「脆弱性, vulnerability」の役割. West LJ ほか (編), 石井 毅 (訳). 精神分裂病の治療-その新しい動向. 東京 : 星和書店 ; 1978. pp6-37.
 
11) Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 1985 ; 46 : 18-21.
PubMed
12) Friedhoff AJ, Simkowitz P. A new conception of the relationship between psychological coping mechanisms and biological stress buffering systems. Br J Psychiatry Suppl 1989 ; 4 : 61-66.
PubMed
13) 岡崎祐士, 太田敏男, 中安信夫. 抗精神病薬の大量療法の検討, その効用と限界. 神経精神薬理 1983 ; 5 : 411-425.
 
14) 諸岡良彦, 平井憲次, 清水高子. 化学的にみたdopamine, およびそのアゴニスト, アンタゴニストと受容体の相互作用. 臨床精神薬理 2009 ; 12 : 2353-2371.
 
15) 八木剛平, 稲田俊也. 新しい分裂病治療薬の模索-いわゆるatypical neurolepticsを中心に. 神経精神薬理 1989 ; 11 : 657-666.
 
16) 八木剛平, 神庭重信, 稲田俊也. 定型および非定型抗精神病薬-分裂病治療薬の新しい動向. 精神医学 1993 ; 35 : 690-701.
 
17) 八木剛平. クロザピン-抗精神病薬の開発史におけるその意義. 脳と精神の医学 1996 ; 7 : 353-362.
 
18) 八木剛平, 渡邊衡一郎, 高野晴成. 原点としてのclozapine (特集「新しい抗精神病薬開発の展開」). 臨床精神薬理 1999 ; 2 : 333-341.
 
19) Bymaster FP, Moore NA, 中沢隆弘. MARTA系抗精神病薬olanzapineの薬理学的基礎. 臨床精神薬理 1999 ; 2 : 885-911.
 
20) 仙波純一. 抗精神病薬の作用機序に関する新しい概念-ドーパミンD2受容体での「速い解離」と部分アゴニスト作用. 精神医学 2003 ; 45 : 916-926.
 
21) Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996 ; 153 : 466-476.
PubMed
22) 八木剛平, 神庭重信, 稲田俊也. 特集・精神分裂病の陽性症状と陰性症状「薬物療法の視点から」. 臨床精神医学 1994 ; 23 : 1305-1310.
 
23) Artaloytia JF, et al. Negative signs and symptoms secondary to antipsychotics : A double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 2006 ; 163 : 488-493.
PubMed
24) Geddes J, et al. Atypical antipsychotics in the treatment of schizophrenia : Systematic overview and meta-regression analysis. BMJ 2000 ; 321 : 1371-1376.
PubMed
25) Hugenholtz GWK, et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia : Comparison with officially recommended doses. J Clin Psychiatry 2006 ; 67 : 897-903.
PubMed
26) Lieberman JA, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 ; 353 : 1209-1223.
PubMed
27) 藤井康男. フィンランドにおける統合失調症初回入院患者についてのNational Register Study-地域での各種抗精神病薬のeffectivenessについての長期的検討. Schizophr Front 2006 ; 7 : 266-271.
 
28) 井上幸紀. 統合失調症における第2世代抗精神病薬とhaloperidolの効果比較. Schizophr Front 2007 ; 8 : 49-53.
 
29) Gaebel W, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode shizophrenia : 1-year results of a randomized controlled trial within the German Research Network on Shizophrenia. J Clin Psychiatry 2007 ; 68 : 1763-1774.
 
30) Jones PB, et al. Randomized controlled trial of the effect of Quality of Life of secondvs first-generation antipsychotic drugs in schizophrenia : Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006 ; 63 : 1079-1087.
PubMed
31) Tandon R. et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008 ; 100 : 20-38.
PubMed
32) Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first-and secondgeneration antipsychotic drugs : A 10-year, retrospective cohort study. J Clin Psychiatry 2009 ; 70 : 122-129.
PubMed
33) Ray WA, et al. Atypical antipsychotic drugs and the risk of sudden death. N Engl J Med 2009 ; 360 : 225-235.
PubMed
34) Woods SW, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications : A prospective cohort study. J Clin Psychiatry 2010 ; 71 : 463-474.
PubMed
35) 伊藤恵子. 心病んだ息子が遺していったもの. 東京 : 日本文学館 ; 2007.
 
36) 北川航平ほか. 統合失調症患者の薬物療法に関する処方実態調査 (2009) 全国134施設の調査から その1, その2. 日本精神神経学会総会, 広島, 2010.
 
37) Mizrahi R, et al. How antipsychotics work : The patients' perspective. Prog Neuro-Psychopharmacol & Biol Psychiatry 2005 ; 29 : 859-864.
 
38) 神田橋條治. 改訂・精神科養生のコツ. 東京 : 岩崎学術出版社 ; 2009.
 
39) 田辺英. 医学哲学からみた発病モデルと回復 (レジリアンス) モデル-自然治癒力思想の興亡. 加藤敏ほか (編). レジリアンス-現代精神医学の新しいパラダイム. 東京 : 金原出版 ; 2009.
 
40) 八木剛平. 精神分裂病の薬物治療学-ネオヒポクラティズムの提唱. 東京 : 金原出版 ; 1993.
 
41) 八木剛平. 臨床医は発病論的治療観から脱却せよ. 精神医学 2004 ; 46 : 910-911.
 
42) 加藤敏ほか (編). レジリアンス-現代精神医学の新しいパラダイム. 東京 : 金原出版 ; 2009. pp51-74.
 
43) 八木剛平, 田亮介, 渡邊衡一郎. 精神疾患の回復論, 生体防御論, そして "Resilience" -統合失調症と気分障害を中心に. 脳と精神の医学 2007 ; 18 : 135-142.
 
44) Stassen HH, et al. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007 ; 68 : 1195-1205.
 
風祭元. 日本近代精神科薬物療法史. 東京 : アークメディア ; 2008.
 
八木剛平, 田辺英. 日本精神病治療史. 東京 : 金原出版 ; 2002.
 
P.30 掲載の参考文献
1) 村崎光邦. Imipramineから50年-わが国における抗うつ薬開発の歴史的展開. 臨床精神薬理 2010 ; 13 : 1831-1846.
 
2) Loomer HP, Saunder JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiat Res Rep Am Psychiatr Assoc 1957 ; 8 : 129-141.
 
3) Kuhn R. Uber die Behandlung depressiver Zustande mit einem Iminodibenzylderivat (G22355). Schweiz Med Wochenschr 1957 ; 87 : 1135-1140.
 
4) Snyder SH. Drugs and the Brain. New York : Scientific American Books ; 1986. / 佐久間昭 (訳). 脳と薬物. 東京 : 東京化学同人 ; 1990. pp91-119.
 
5) Rapoport JL. The biology of obsessions and compulsions. Sci Am 1989 ; 260 : 82-89.
PubMed
6) Deakin JFW, et al. Experimental tests of the 5-HT receptor imbalance theory of affective disturbance. In : Sandler M, et al (eds). 5-Hydroxytryptamine in Psychiatry, A Spectrum of Ideas. Oxford : Oxford University Press ; 1991. pp143-156.
 
7) 中嶋照夫. 不安・抑うつと強迫の神経生物学. 精神神経誌 1998 ; 100 : 146-151.
 
8) Kennett GA, Dourish CT, Curzon G. Antidepressant-like action of 5-HT 1A agonists and conventional antidepressants in an animal model of depression. Eur J Pharmacol 1987 ; 134 : 265-274.
 
P.44 掲載の参考文献
1) Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of γ-aminobutyric acid receptor channeles by diazepam and phenobarbital. Ann Neurol 1989 ; 25 : 213-220.
 
2) Polc P, et al. A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro15-1788, benzodiazepine tranquilizers, β-carbolines and phenobarbitone. Naunyn Schmiedebergs Arch Pharmacol 1982 ; 321 : 260-264.
 
3) Berger HM. Anxiety and the discovery of the tranquilizers. In : Ayd FJ, et al (eds). Discoveries in Biological Psychiatry. Philadelphia : Lippincott ; 1970. pp115-129.
 
4) Lemere F. Habit-forming properties of meprobamate (Miltown or Equanil). AMA Arch Neurol Psychiatry 1956 ; 76 : 205-206.
PubMed
5) Sternbach LH. The benzodiazepine story. J Med Chem 1979 ; 22 : 1-7.
 
6) 田原哲冶. チエノジアゼピン物語 (Etizolam). 臨床精神薬理 1999 ; 2 : 399-402.
 
7) Meguro K, Kuwada Y. Syntheses and structures of 7-chloro-2-hydrazino-5-phenyl-3H-1, 4-benzodiazepines and some isomeric 1, 4, 5-benzotriazocines. Chem Pharm Bull 1973 ; 21 : 2375-2381.
 
8) Costa E, Guidotti A. Molecular mechanisms in the receptor action of benzodiazepines. Annu Rev Pharmacol 1979 ; 19 : 531-545.
 
9) Hamill OP, Bormann J, Sakmann B. Activation of multiple-conductance state chloride channels in spinal neurons by glycine and GABA. Nature 1983 ; 305 : 805-808.
PubMed
10) Braestrup C, Squires RF. Specific benzodiazepine receptors in rat brain characterized by high-affinity 3 H-diazepam binding. Proc Natl Acad Sci U S A 1977 ; 74 : 3805-3809.
 
11) Mohler H, Okada T. Benzodiazepine receptors : Demonstration in the central nervous system. Science 1977 ; 198 : 849-851.
PubMed
12) Rosmann HB, Case KR, DiStefano P. Diazepam receptor characterization : Specific binding of a benzodiazepine to macromolecules in various areas of rat brain. FEBS Lett 1977 ; 82 : 368-372.
 
13) Eison AS, Temple DL Jr. Buspirone : Review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986 ; 80 (Suppl 33) : 1-9.
 
14) Eison MS. Azapirones : Clinical uses of serotonin partial agonists. Fam Pract Recert 1989 ; 11 (Suppl) : 8-16.
 
15) Shimizu H, et al. Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn J Pharmacol 1992 ; 59 : 105-112.
PubMed
16) 村崎光邦. Tandospironeの基礎と臨床. 臨床精神薬理 1998 ; 1 : 81-92.
 
17) Lader M. Dependence on benzodiazepines. J Clin Psychiatry 1983 ; 44 : 121-127.
PubMed
18) Tyrer P, Seivewright N. Identification and management of benzodiazepine dependence. Postgrad Med J 1984 ; 60 (Suppl 2) : 41-46.
 
19) 村崎光邦. 抗不安薬の臨床用量依存. 精神神経誌 1996 ; 98 : 612-621.
 
20) Stahl SM. Antidepressants : The blue-chip psychotropic for the modern treatment of anxiety disorders. J Clin Psychiatry 1999 ; 60 : 356-357.
PubMed
21) Stahl SM. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 2002 ; 63 : 756-757.
 
22) 村崎光邦. Benzodiazepine 系抗不安薬の歴史的使命と今後の動向について. 臨床精神薬理 2006 ; 9 : 2421-2431.
 
23) 上條吉人ほか. 「完全自殺マニュアル」による自殺企図. 精神分裂病者の大量服薬. 精神医学 1996 ; 38 : 267-273.
 
24) Kales A, Scharf MB, Kales JD. Rebound insomnia : A new clinical syndrome. Science 1978 ; 201 : 1039-1041.
PubMed
25) Vogel G, et al. The effect of triazolam on the sleep of insomniacs. Psychopharmacologia 1975 ; 41 : 65-69.
PubMed
26) van der Kroef C. Reactions to triazolam. Lancet 1979 ; 2 : 526.
PubMed
27) 村崎光邦. 短時間作用型睡眠薬の動向-Halcion storyを通して. 太田龍朗 (編). 睡眠・覚醒とその障害. 精神医学レビュー 4. 東京 : ライフサイエンス ; 1992. pp80-92.
 
28) 菅野道. 新しい睡眠薬の臨床. 臨床精神医学 1990 ; 19 : 197-205.
 
29) Langer SZ, Arbilla S. Limitations of the benzodiazepine receptor nomenclature : A proposal for a pharmacological classification as omega receptor subtypes. Fundam Clin Pharmacol 1988 ; 2 : 159-170.
PubMed
30) Rudolph U, et al. Benzodiazepine actions mediated by specific γ-aminobutyric acid A receptor subtypes. Nature 1999 ; 401 : 796-800.
 
31) 村崎光邦. Zolpidemの基礎と臨床. 臨床精神薬理 2001 ; 4 (増刊号) : 147-169.
 
32) McCord CP, Allen FP. Evidences associating pineal gland function with alterations in pigmentation. J Exptl Zool 1917 ; 23 : 207-224
 
33) Lerner AB, et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958 ; 80 : 2587.
 
34) Dubocovich ML. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 2003 ; 8 : 1093-1108.
 
35) 平井圭介. ラメルテオンの作用メカニズム. 睡眠医療 2010 ; 4 (増刊号) : 164-168.
 
36) 村崎光邦. 新規睡眠薬ramelteonの基礎と臨床. 臨床精神薬理 2011 ; 14 : 419-438.
 
37) Hajak G, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone : A review of case reports and epidemiological data. Addiction 2003 ; 98 : 1371-1378.
PubMed

II 薬物療法の到達点

P.54 掲載の参考文献
1) Ray WA, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009 ; 360 (3) : 225-235.
PubMed
2) Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergic over the course of a 10 year prospective study. Br J Psychiatry 1998 ; 173 : 325-329.
PubMed
3) Kane J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 ; 45 : 789-796.
PubMed
4) Nordstrom AL, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects : A double-blind PET study of schizophrenic patients. Biol Psychiatry 1993 ; 33 (4) : 227-235.
PubMed
5) Essock SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006 ; 163 : 2090-2095.
PubMed
6) Lehman AF, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004 ; 161 (2 Suppl) : 1-56.
 
大森哲郎. 多剤併用療法を臨床薬理学から考える. 精神科治療学 2003 ; 18 : 765-770.
 
大森哲郎. 抗精神病薬の用量反応性. 臨床精神薬理 2005 ; 8 : 1175-1183.
 
大森哲郎. 統合失調症の治療. 日本臨床精神神経薬理学会専門医制度委員会 (編). 臨床精神神経薬理学テキスト, 改訂第2版. 東京 : 星和書店 ; 2008. pp340-349.
 
P.61 掲載の参考文献
1) Lewis DA, Lieberman JA. Catching up on schizophrenia : Natural history and neurobiology. Neuron 2000 ; 28 : 325-334.
PubMed
2) Andreasen NC, et al. Remission in schizophrenia : Proposed criteria and rationale for consensus. Am J Psychiatry 2005 ; 162 : 441-449.
PubMed
3) Liberman RP, et al. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry 2002 ; 14 : 256-272.
 
4) Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006 ; 39 : 161-170.
PubMed
5) Robinson DG, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004 ; 161 : 473-479.
PubMed
6) Wunderink L, et al. Clinical recovery in first-episode psychosis. Schizophrenia Bull 2009 ; 35 : 362-369.
PubMed
P.70 掲載の参考文献
1) Cannon M, Jones P. Schizophrenia. J Neurol Neurosurg Psychiatry 1996 ; 60 (6) : 604-613.
PubMed
2) Crow TJ, et al. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986 ; 148 : 120-127.
PubMed
3) Gitlin M, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001 ; 158 (11) : 1835-1842.
PubMed
4) Kane JM, et al. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982 ; 39 (1) : 70-73.
PubMed
5) Hogarty GE, et al. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Dis Nerv Syst 1976 ; 37 (9) : 494-500.
PubMed
6) Lehman AF, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004 ; 161 (2 Suppl) : 1-56.
 
7) Kane JM, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998 ; 8 (1) : 55-66.
PubMed
8) Boter H, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission : An open randomized clinical trial (EUFEST). Schizophr Res 2009 ; 115 (2-3) : 97-103.
PubMed
9) Kahn RS, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder : An open randomised clinical trial. Lancet 2008 ; 371 (9618) : 1085-1097.
PubMed
10) 渡邊衡一郎, 竹内啓善, 菊地俊暁. 飲み心地を重視した統合失調症治療のすすめ. 精神科治療学 2010 ; 25 (3) : 335-345.
 
11) Hogan MF. The President's New Freedom Commission : Recommendations to transform mental health care in America. Psychiatr Serv 2003 ; 54 (11) : 1467-1474.
PubMed
12) 澤田法英, 渡邊衡一郎. 抗うつ薬をどのように処方するか-アドヒアランス向上の観点から. うつ病治療のエクセレンス. 東京 : アルタ出版 ; 2010. pp55-62.
 
13) 渡邊衡一郎. さらなるアドヒアランスの向上に向けて我々が取り組めること. 臨床精神薬理 2008 ; 11 (4) : 749-759.
 
14) Weiden PJ, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004 ; 55 (8) : 886-891.
PubMed
15) Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia : Our patients can do better. J Clin Psychiatry 2003 ; 64 (11) : 1308-1315.
 
16) Perkins DO, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder : A randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008 ; 69 (1) : 106-113.
 
17) 澤田法英, 渡邊衡一郎. アドヒアランス-最近の動向. 精神科 2007 ; 11 (6) : 433-440.
 
18) 澤田法英. 統合失調症患者の薬物アドヒアランスの基本データをまとめてください. 藤井康男 (監修). LAIマスターブック. 東京 : アルタ出版 ; 2010. pp14-18.
 
19) Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia : Empirical and clinical findings. Schizophr Bull 1997 ; 23 (4) : 637-651.
PubMed
20) 渡邊衡一郎. 服薬アドヒアランスと治療予後. Schizophrenia Frontier 2004 ; 5 (4) : 252-259.
Medical*Online
21) 澤田法英, 渡邊衡一郎. 統合失調症のアドヒアランス. 臨床精神薬理 2008 ; 11 (9) : 1633-1644.
 
22) Lacro JP, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia : A comprehensive review of recent literature. J Clin Psychiatry 2002 ; 63 (10) : 892-909.
PubMed
23) Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998 ; 49 (2) : 196-201.
PubMed
24) Sawada N, et al. Persistence and compliance to antidepressant treatment in patients with depression : A chart review. BMC Psychiatry 2009 ; 9 : 38.
PubMed
25) 三澤史斉. 統合失調症治療における部分アドヒアランス対策の重要性. 臨床精神薬理 2009 ; 12 (6) : 1115-1123.
 
26) Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients : A population-based study in schizophrenia. J Clin Psychiatry 2007 ; 68 (6) : 818-825.
PubMed
27) 澤田法英. 第2世代抗精神病薬の出現で薬物アドヒアランスの問題は解決したのですか. 藤井康男 (監修). LAI マスターブック. 東京 : アルタ出版 ; 2010. pp18-21.
 
28) Olivares JM, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain : Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009 ; 24 (5) : 287-296.
 
29) 上島国利, 津村哲彦. 精神科外来薬物療法の問題点. 精神神経誌 1981 ; 83 : 691-699.
 
30) Velligan DI, et al. The expert consensus guideline series : Adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009 ; 70 Suppl 4 : 1-46 ; quiz 47-48.
 
31) Cooper C, et al. Why people do not take their psychotropic drugs as prescribed : Results of the 2000 National Psychiatric Morbidity Survey. Acta Psychiatr Scand 2007 ; 116 : 47-53.
 
32) Emanuel EJ, Emanuel LL. Four models of the physician-patient relationship. JAMA 1992 ; 267 (16) : 2221-2226.
PubMed
33) 渡邊衡一郎. うつ病の外来診療におけるヒント-お薬の上手な使い方について. 神田橋條治ほか. 座談会 うつ病治療-現場の工夫より. 大阪 : メディカルレビュー社 ; 2010. pp208-232.
 
34) Hamann J, et al. Patient participation in antipsychotic drug choice decisions. Psychiatry Res 2010 ; 178 (1) : 63-67.
PubMed
35) Hamann J, et al. Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry 2007 ; 68 (7) : 992-997.
PubMed
藤井康男 (監修). LAI マスターブック. 東京 : アルタ出版 ; 2010.
 
Albert Michael. OSCEs in Psychiatry : Prepare for the New MRCPsych. Churchill Livingstone ; 2004. / 澤田法英, 渡邊衡一郎 (監訳). 読むだけでコツがつかめる問診力トレーニング. 東京 : アルタ出版 ; 2010.
 
Taylor D, Paton C, Kapur S. Maudsley Prescribing Guidelines 10th eds. London : Informa Healthcare ; 2009/内田裕之, 鈴木健文, 渡邊衡一郎 (監訳). モーズレイ処方ガイドライン. 東京 : アルタ出版 ; 2011.
 
P.79 掲載の参考文献
1) Clark RE, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder : Implications for state mental health policy. Schizophr Bull 2002 ; 28 : 75-84.
PubMed
2) Lehman AF, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Arlington, VA : American Psychiatric Association ; 2004.
 
3) Taylor D, Paton C, Kerwin R. The Maudsley prescribing guidelines 9th Edition. London : Informa Healthcare ; 2009.
 
4) Moore TA, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia : 2006 update. J Clin Psychiatry 2007 ; 68 : 1751-1762.
PubMed
5) International Psychopharmacology Algorithm Project (IPAP). Schizophrenia Algorithm, 2006. http://www.ipap.org/schiz/index.php
 
6) Kane JM, et al. The expert consensus guideline series Optimizing Pharmacologic Treatment of Psychotic Disorders. J Clin Psychiatry 2003 ; 64 (Suppl 12) : 5-94.
 
7) 山本暢朋, 稲田俊也, 藤井康男. 気分安定薬を用いた統合失調症の効果増強療法. 臨床精神薬理 2010 ; 13 : 1961-1973.
 
8) Terao T, et al. Lithium addition to neuroleptic treatment in chronic schizophrenia : A randomized, double-blind, placebo-controlled, cross-over study. Acta Psychiatr Scand 1995 ; 92 : 220-224.
PubMed
9) Wilson WH. Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia : A double blind, placebo controlled, parallel design clinical trial. Psychopharmacology (Berl) 1993 ; 111 : 359-366.
PubMed
10) Leucht S, Kissling W, McGrath J. Lithium for schizophrenia revisited : A systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2004 ; 65 : 177-186.
PubMed
11) Casey DE, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003 ; 28 : 182-192.
 
12) Casey DE, et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacol 2009 ; 34 : 1330-1338.
PubMed
13) Basan A, Kissling W, Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia : A systematic review of randomized trials. Schizophr Res 2004 ; 70 : 33-37.
PubMed
14) Okuma T, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989 ; 80 : 250-259.
 
15) Dose M, Apelt S, Emrich HM. Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res 1987 ; 22 : 303-310.
PubMed
16) Nachshoni T, et al. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatry 1994 ; 35 : 22-26.
PubMed
17) Hesslinger B, et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999 ; 19 : 310-315.
 
18) Leucht S, et al. Carbamazepine augmentation for schizophrenia : How good is the evidence? J Clin Psychiatry 2002 ; 63 : 218-224.
PubMed
19) Zoccali R, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients : A double-blind, placebo-controlled study. Schizophr Res 2007 ; 93 : 109-116.
 
20) Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia : A systematic review and meta-analysis. Schizophr Res 2009 ; 109 : 10-14.
PubMed
21) Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev 2006 ; CD005962.
PubMed
22) Tiihonen J, et al. Topiramate add-on in treatment-resistant schizophrenia : A randomized, double-blind, placebo-controlled, crossover trial. J Clin Psychiatry 2005 ; 66 : 1012-1015.
PubMed
23) Afshar H, et al. Topiramate add-on treatment in schizophrenia : A randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 2009 ; 23 : 157-162.
PubMed
24) Whitehead C, et al. Antidepressants for people with both schizophrenia and depression Cochrane Database Syst Rev 2002 ; CD002305.
PubMed
25) Kirli S, Caliskan M. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophr Res 1998 ; 33 : 103-111.
 
26) 山本暢朋, 稲田俊也. Q53. 藤井康男 (編). 統合失調症の薬物療法100のQ&A. 東京 : 星和書店 ; 2008. pp176-178.
 
27) Jockers-Scherubl MC, et al. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics : A double-blind placebo-controlled study. Int Clin Psychopharmacol 2005 ; 20 : 27-31.
PubMed
28) Abbasi SH, et al. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia : A double-blind randomized placebo-controlled trial. Schizophr Res 2010 ; 116 : 101-106.
 
29) Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms : A systematic review of randomized trials. Schizophr Res 2005 ; 80 : 85-97.
PubMed
30) Sepehry AA, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia : A meta-analysis. J Clin Psychiatry 2007 ; 68 : 604-610.
 
31) Barbee JG, et al. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry 1992 ; 149 : 506-510.
PubMed
32) Altamura AC, et al. Clonazepam/haloperidol combination therapy in schizophrenia : A double blind study. Acta Psychiatr Scand 1987 ; 76 : 702-706.
PubMed
33) Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia : A review and reappraisal. Am J Psychiatry 1991 ; 148 : 714-726.
PubMed
34) Schmider J, et al. A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism. Biol Psychiatry 1999 ; 46 : 437-441.
PubMed
35) Takkouche B, et al. Psychotropic medications and the risk of fracture : A meta-analysis. Drug Saf 2007 ; 30 : 171-184.
PubMed
36) Akhondzadeh S, et al. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008 ; 32 : 1810-1815.
PubMed
37) Caspi N, et al. Pindolol augmentation in aggressive schizophrenic patients : A double-blind crossover randomized study. Int Clin Psychopharmacol 2001 ; 16 : 111-115.
PubMed
38) Cheine M, Ahonen J, Wahlbeck K. Beta-blocker supplementation of standard drug treatment for schizophrenia. Cochrane Database Syst Rev 2000.
 
39) Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia : A double blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2005 ; 29 : 253-259.
 
40) Akhondzadeh S, et al. Adjunctive estrogen treatment in women with chronic schizophrenia : A double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2003 ; 27 : 1007-1012.
PubMed
稲田俊也 (編). 各種ガイドライン・アルゴリズムから学ぶ統合失調症の薬物療法. 東京 : アルタ出版 ; 2006.
 
P.88 掲載の参考文献
1) Seeman P. Atypical antipsychotics : Mechanism of action. Can J Psychiatry 2002 ; 47 : 27-38.
PubMed
2) Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998 ; 3 : 123-134.
PubMed
3) Kusumi I, et al. Risperidone oral solution versus standard tablets for the acute treatment of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010 ; doi : 10.1016/j. pnpbp. 2010.12.010 (online).
 
4) 久住一郎, 小山司. 統合失調症再発予防効果におけるドパミンの役割. 臨床精神薬理 2008 ; 11 : 1451-1456.
 
5) 久住一郎, 高橋義人, 小山司. Perospironeの適応と用量反応性. 臨床精神薬理 2005 ; 8 : 1219-1225.
 
6) Kusumi I, Masui T, Koyama T. Long-term perospirone treatment with a single dose at bedtime in schizophrenia : Relevant to intermittent dopamine D2 receptor antagonism. Prog Neuropsychopharmacol Biol Psychiatry 2008 ; 32 : 520-522.
PubMed
7) Arakawa R, et al. Dopamine D 2 receptor occupancy by perospirone : A positron emission tomography study in patients with schizophrenia and healthy subjects. Psychopharmacology 2010 ; 209 : 285-290.
PubMed
P.99 掲載の参考文献
1) Wright IC, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000 ; 157 (1) : 16-25.
PubMed
2) Honea R, et al. Regional deficits in brain volume in schizophrenia : A meta-analysis of voxel-based morphometry studies. Am J Psychiatry 2005 ; 162 (12) : 2233-2245.
PubMed
3) Bose SK, et al. The effect of ageing on grey and white matter reductions in schizophrenia. Schizophr Res 2009 ; 112 (1-3) : 7-13.
 
4) Nenadic I, et al. Aging Effects on Regional Brain Structural Changes in Schizophrenia. Schizophr Bull 2011.
PubMed
5) Pantelis C, et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull 2005 ; 31 (3) : 672-696.
PubMed
6) Kasai K, et al. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. Am J Psychiatry 2003 ; 160 (1) : 156-164.
PubMed
7) Kasai K, et al. Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia : A longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2003 ; 60 (8) : 766-775.
PubMed
8) Pantelis C, et al. Neuroanatomical abnormalities before and after onset of psychosis : A cross-sectional and longitudinal MRI comparison. Lancet 2003 ; 361 (9354) : 281-288.
PubMed
9) Wood SJ, et al. Progressive changes in the development toward schizophrenia : Studies in subjects at increased symptomatic risk. Schizophr Bull 2008 ; 34 (2) : 322-329.
PubMed
10) Lieberman JA, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005 ; 62 (4) : 361-370.
PubMed
11) Chakos MH, et al. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 1995 ; 345 (8947) : 456-457.
PubMed
12) McCormick L, et al. Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia. Schizophr Res 2005 ; 80 (1) : 73-84.
PubMed
13) Tomelleri L, et al. Brain structural changes associated with chronicity and antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 2009 ; 19 (12) : 835-840.
 
14) Dazzan P, et al. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis : The AESOP study. Neuropsychopharmacology 2005 ; 30 (4) : 765-774.
PubMed
15) Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry 2005 ; 58 (1) : 62-66.
PubMed
16) Kanaan RA, et al. Diffusion tensor imaging in schizophrenia. Biol Psychiatry 2005 ; 58 (12) : 921-929.
PubMed
17) Kubicki M, et al. A review of diffusion tensor imaging studies in schizophrenia. J Psychiatr Res 2007 ; 41 (1-2) : 15-30.
 
18) Kyriakopoulos M, et al. A diffusion tensor imaging study of white matter in earlyonset schizophrenia. Biol Psychiatry 2008 ; 63 (5) : 519-523.
PubMed
19) Kuroki N, et al. Fornix integrity and hippocampal volume in male schizophrenic patients. Biol Psychiatry 2006 ; 60 (1) : 22-31.
PubMed
20) Minami T, et al. Diffusion tensor magnetic resonance imaging of disruption of regional white matter in schizophrenia. Neuropsychobiology 2003 ; 47 (3) : 141-145.
PubMed
21) Okugawa G, et al. Subtle disruption of the middle cerebellar peduncles in patients with schizophrenia. Neuropsychobiology 2004 ; 50 (2) : 119-123.
PubMed
22) Goff DC, et al. Tardive dyskinesia and substrates of energy metabolism in CSF. Am J Psychiatry 1995 ; 152 (12) : 1730-1736.
PubMed
23) Post A, Holsboer F, Behl C. Induction of NF-kappaB activity during haloperidolinduced oxidative toxicity in clonal hippocampal cells : Suppression of NF-kappaB and neuroprotection by antioxidants. J Neurosci 1998 ; 18 (20) : 8236-8246.
PubMed
24) Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry : What is happening in the schizophrenic brain? Arch Gen Psychiatry 2002 ; 59 (6) : 553-558.
PubMed
25) Vita A, De Peri L. The effects of antipsychotic treatment on cerebral structure and function in schizophrenia. Int Rev Psychiatry 2007 ; 19 (4) : 429-436.
 
26) Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol Med 2009 ; 39 (11) : 1763-1777.
PubMed
27) Agid O, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia. Neuropsychopharmacology 2007 ; 32 (6) : 1209-1215.
PubMed
28) Kegeles LS, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F] fallypride. Neuropsychopharmacology 2008 ; 33 (13) : 3111-3125.
PubMed
29) Bressan RA, et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I] epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 2003 ; 160 (8) : 1413-1420.
 
30) Pilowsky LS, et al. Limbic selectivity of clozapine. Lancet 1997 ; 350 (9076) : 490-491.
PubMed
31) Stone JM, et al. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull 2009 ; 35 (4) : 789-797.
PubMed
32) Raedler TJ, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003 ; 160 (1) : 118-127.
PubMed
33) Mu Q, et al. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res 2007 ; 94 (1-3) : 332-341.
PubMed
34) Stone JM, et al. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy : A [(123)I] CNS-1261 SPET study. Psychopharmacology (Berl) 2008 ; 197 (3) : 401-408.
PubMed
35) Benarroch EE. N-acetylaspartate and N-acetylaspartylglutamate : Neurobiology and clinical significance. Neurology 2008 ; 70 (16) : 1353-1357.
 
36) Moffett JR, et al. N-Acetylaspartate in the CNS : From neurodiagnostics to neurobiology. Prog Neurobiol 2007 ; 81 (2) : 89-131.
PubMed
37) Rigotti DJ, Inglese M, Gonen O. Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 2007 ; 28 (10) : 1843-1849.
 
38) Ohrmann P, et al. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients : A proton magnetic resonance spectroscopy study. J Psychiatr Res 2007 ; 41 (8) : 625-634.
PubMed
39) Braus DF, et al. Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics : An MRSI study. Pharmacopsychiatry 2001 ; 34 (6) : 251-253.
 
40) Bertolino A, et al. The effect of treatment with antipsychotic drugs on brain Nacetylaspartate measures in patients with schizophrenia. Biol Psychiatry 2001 ; 49 (1) : 39-46.
PubMed
41) Agarwal N, et al. Update on the use of MR for assessment and diagnosis of psychiatric diseases. Radiology 2010 ; 255 (1) : 23-41.
PubMed
42) Theberge J, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003 ; 160 (12) : 2231-2233.
 
43) Theberge J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002 ; 159 (11) : 1944-1946.
 
44) Stone JM, et al. Glutamate dysfunction in people with prodromal symptoms of psychosis : Relationship to gray matter volume. Biol Psychiatry 2009 ; 66 (6) : 533-539.
PubMed
45) Jensen JE, et al. Focal changes in brain energy and phospholipid metabolism in firstepisode schizophrenia : 31P-MRS chemical shift imaging study at 4 Tesla. Br J Psychiatry. 2004 ; 184 : 409-415.
PubMed
46) van de Ven VG, et al. The spatiotemporal pattern of auditory cortical responses during verbal hallucinations. Neuroimage 2005 ; 27 (3) : 644-655.
PubMed
47) McGuire P, et al. Functional neuroimaging in schizophrenia : Diagnosis and drug discovery. Trends Pharmacol Sci 2008 ; 29 (2) : 91-98.
PubMed
48) Davis CE, Jeste DV, Eyler LT. Review of longitudinal functional neuroimaging studies of drug treatments in patients with schizophrenia. Schizophr Res 2005 ; 78 (1) : 45-60.
PubMed
49) Snitz BE, et al. Lateral and medial hypofrontality in first-episode schizophrenia : Functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am J Psychiatry 2005 ; 162 (12) : 2322-2329.
 
50) Wolf RC, et al. Changes over time in frontotemporal activation during a working memory task in patients with schizophrenia. Schizophr Res 2007 ; 91 (1-3) : 141-150.
 
51) Sambataro F, et al. Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia. Neuropsychopharmacology 2010 ; 35 (4) : 904-912.
PubMed
52) Stephan KE, et al. Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychol Med 2001 ; 31 (6) : 1065-1078.
PubMed
53) Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996 ; 153 (3) : 321-330.
PubMed
54) Bertolino A, et al. Interaction of COMT (Val (108/158) Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004 ; 161 (10) : 1798-1805.
PubMed
55) Sava S, Yurgelun-Todd DA. Functional magnetic resonance in psychiatry. Top Magn Reson Imaging 2008 ; 19 (2) : 71-79.
 
P.109 掲載の参考文献
1) Furukawa TA, et al. How many well vs. unwell days can you expect 10 years, once you become depressed? Acta Psychiatr Scand 2009 ; 119 (4) : 290-297.
PubMed
2) 塩江邦彦, 平野雅己, 神庭重信. 大うつ病性障害の治療アルゴリズム. 本橋伸高, 精神科薬物療法研究会 (編). 気分障害の治療アルゴリズム. 東京 : じほう ; 2003. pp19-46.
 
3) Kielholz P, 清水信 (訳). 抗うつ薬の作用スペクトラム. 臨床精神医学 1978 ; 7 : 807-814.
 
4) Ueda N, et al. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 2002 ; 35 : 175-181.
PubMed
5) Shinkai K, et al. Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 2004 ; 24 : 11-17.
PubMed
6) Umene-Nakano W, et al. Predictive factors for responding to sertraline treatment : Views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol 2010 ; 24 : 1764-1771.
PubMed
7) Karege F, et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002 ; 109 : 143-148.
PubMed
8) Karege F, et al. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002 ; 16 : 261-264.
 
9) Pillai A, et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects : Correlation with plasma and psychopathology. Int J Neuropsychopharmacol 2010 ; 13 : 535-539.
PubMed
10) Zou YF, et al. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 2010 ; 20 : 535-544.
PubMed
11) Tradic A, et al. The early non-increase of serum BDNF predicts falure of antidepressant treatment in patients with major depression : A pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2011 ; 35 : 415-420.
 
12) Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders : An historical overview and future directions. Psychiatry Clin Neurosci 2010 ; 64 : 341-357.
PubMed
13) 吉村玲児. 自殺予防の観点から見たうつ病の治療. 精神神経誌 2007 ; 109 : 822-833.
 
Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006 ; 59 : 1116-1127.
PubMed
Belmarker RH, Agam G. Major depressive disorder. N Engl J Med 2008 ; 358 : 55-68.
 
aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ 2009 ; 180 : 305-313.
PubMed
Sandi C, Richter-Levin G. From high anxiety trait to depression : A neurocognitive hypothesis. Trends Neurosci 2009 ; 32 : 312-320.
PubMed
P.116 掲載の参考文献
1) Keitner GI, Ryan CE, Solomon DA. Realistic expectations and a disease management model for depressed patients with persistent symptoms. J Clin Psychiatry 2006 ; 67 : 1412-1421.
 
2) Frank E, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder : Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991 ; 48 : 851-855.
PubMed
3) Judd LL, et al. Major depressive disorder : A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998 ; 50 : 97-108.
PubMed
4) Patten SB, et al. Long-term medical conditions and major depression : Strength of association for specific conditions in the general population. Can J Psychiatry 2005 ; 50 : 195-202.
PubMed
5) 石郷岡純. SSRIによるうつ病治療の現状と留意点. 臨床精神薬理 2006 ; 9 : 1407-1423.
 
6) Wells KB, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989 ; 262 : 914-919.
PubMed
7) 中村純, 石郷岡純. 寛解, 回復を目指したうつ病の治療-うつ病の寛解, 回復の概念, 定義. 臨床精神薬理 2008 ; 11 : 405-411.
 
8) Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991 ; 52 (Suppl) : 28-34.
 
9) Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3 : Psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998 ; 59 : 608-619.
PubMed
10) 青葉安里ほか. うつ病またはうつ状態の患者を対象とした塩酸パロキセチン水和物の健康関連QOLの検討 (第2報) -何が健康関連QOL改善に寄与したのか. 臨床精神薬理 2005 ; 8 : 1063-1075.
 
11) Fricchione GL, et al. Potential intervention for depression associated with increased mortality risk in patients after myocardial infarction. Am J Cardiol 2002 ; 89 : 112-113.
PubMed
12) Rutledge T, et al. Depression symptom severity and reported treatment history in the prediction of cardiac risk in women with suspected myocardial ischemia : The NHLBI-sponsored WISE study. Arch Gen Psychiatry 2006 ; 63 : 874-880.
PubMed
13) Lesperance F, et al. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002 ; 105 : 1049-1053.
PubMed
14) Zimmerman M, et al. How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry 2006 ; 163 : 148-150.
 
15) Paykel ES, et al. Residual symptoms after partial remission : An important outcome in depression. Psychol Med 1995 ; 25 : 1171-1180.
PubMed
16) McIntyre RS, Fallu A, Konarski JZ. Measurable outcomes in psychiatric disorders : Remission as a marker of wellness. Clin Ther 2006 ; 28 : 1882-1891.
PubMed
17) Melartin TK, et al. Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry 2005 ; 66 : 220-227.
 
18) Sawada N, et al. Persistence and compliance to antidepressant treatment in patients with depression : A chart review. BMC Psychiatry 2009 ; 9 : 38.
PubMed
19) 渡邊衡一郎, 菊地俊暁. 抗うつ薬服用者を対象としたウェブ調査2008の結果に見る患者の気持ち. 臨床精神薬理 2008 ; 11 : 2295-2304.
 
20) 佐々木亜紀ほか. うつ病クリニカルパスに則った服薬指導の評価. 日本病院薬剤師会雑誌 2007 ; 43 (6) : 817-821.
Medical*Online
21) Reimherr FW, et al. Optimal length of continuation therapy in depression : A prospective assessment during long-term fluoxetine treatment. Am J Psychiatry 1998 ; 155 : 1247-1253.
PubMed
22) Bull SA, et al. Discontinuation of use and switching of antidepressants : Influence of patient-physician communication. JAMA 2002 ; 288 : 1403-1409.
PubMed
P.124 掲載の参考文献
1) Spijker J, Nolen WA. An algorithm for the pharmacological treatment of depression. Acta Psychiatr Scand 2010 ; 121 (3) : 180-189.
PubMed
2) Rush AJ, et al. STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006 ; 354 (12) : 1231-1242.
PubMed
3) Ruhe HG, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder : A systematic review. J Clin Psychiatry 2006 ; 67 (12) : 1836-1855.
PubMed
4) Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression : A meta-analysis comparing within-versus across-class switches. Biol Psychiatry 2008 ; 63 (7) : 699-704.
PubMed
5) 井上猛, 鈴木克治, 小山司. 難治性うつ病に対するドパミン・アゴニストの臨床効果. 臨床精神医学 2009 ; 38 (8) : 1093-1104.
Medical*Online
6) Blier P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder : A double-blind randomized study. Am J Psychiatry 2010 ; 167 (3) : 281-288.
PubMed
Anderson IM, et al. Evidence-based guidelines for treating depressive disorders with antidepressants : A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008 ; 22 (4) : 343-396.
PubMed
Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009 ; 117 (Suppl 1) : S26-43.
 
Papakostas GI. Managing partial response or nonresponse : Switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009 ; 70 (Suppl 6) : 16-25.
 
Spijker J, Nolen WA. An algorithm for the pharmacological treatment of depression. Acta Psychiatr Scand 2010 ; 121 (3) : 180-189.
PubMed
Work Group On Major Depressive Disorder. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. American Psychiatric Association ; November 2010. http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx
 
P.134 掲載の参考文献
1) 日本うつ病学会 抗うつ薬の適正使用に関する委員会. SSRI/SNRIを中心とした抗うつ薬適正使用に関する提言. 2009年10月30日 http://www.secretariat.ne.jp/jsmd/koutsu/pdf/antidepressant%20.pdf
 
2) Kirsch I, et al. Initial severity and antidepressant benefits : A meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008 ; 5 : e45.
 
3) 日本うつ病学会, 日本臨床精神神経薬理学会. 新規抗うつ薬検討ワーキンググループ委員会報告. 2008年12月15日 http://www.secretariat.ne.jp/jsmd/link/pdf/workgroup081215.pdf
 
4) Fournier JC, et al. Antidepressant drug effects and depression severity : A patientlevel meta-analysis. JAMA 2010 ; 303 : 47-53.
PubMed
5) Uhlenhuth EH, et al. Predicting the relief of anxiety with meprobamate. Nondrug factors in the response of psychoneurotic outpatients. Arch Gen Psychiatry 1968 ; 19 : 619-630.
 
6) Uhlenhuth EH, et al. Growing placebo response rate : The problem in recent therapeutic trials? Psychopharmacol Bull 1997 ; 33 : 31-39.
PubMed
7) 石郷岡純. SSRIによるうつ病治療の現状と留意点. 臨床精神薬理 2006 ; 9 : 1407-1423.
 
8) 高橋一志, 石郷岡純.様々なうつ病治療における寛解率の違い. 臨床精神薬理 2008 ; 11 : 413-420.
 
9) Perry PJ. Pharmacotherapy for major depression with melancholic features : Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996 ; 39 : 1-6.
PubMed
石郷岡純. プラセボ比較試験の問題点再考. 臨床精神薬理 2005 ; 8 : 1407-1414.
 
P.147 掲載の参考文献
1) Akiskal HS. Sofy Bipolarity-A footnote to Kraepelin 100 years later. 臨床精神病理 2000 ; 21 : 3-11.
 
2) Ghaemi SN, Ko JY, Goodwin FK. The bipolar spectrum and the antidepressant view of the world. J Psychiatr Pract 2001 ; 7 (5) : 287-297.
 
3) Tohen M, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009 ; 11 (5) : 453-473.
PubMed
4) Kornum JB, et al. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations : Updated analysis. Clin Epidemiol 2010 ; 2 : 29-36.
PubMed
5) Tohen M, Waternaux CM, Tsuang MT. Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990 ; 47 (12) : 1106-1111.
 
6) Keller MB, et al. Bipolar I : A five-year prospective follow-up. J Nerv Ment Dis 1993 ; 181 (4) : 238-245.
 
7) Goodwin FK, Jamison KR. Manic-Depressive Illness : Bipolar Disorders and Recurrent Depression, 2nd edition. New York : Oxford University Press ; 2007.
 
8) Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974 ; 30 (2) : 229-233.
PubMed
9) Otto MW, et al. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry 2006 ; 189 : 20-25.
PubMed
10) Judd LL, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003 ; 60 (3) : 261-269.
 
11) Judd LL, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002 ; 59 (6) : 530-537.
 
12) Calabrese JR, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005 ; 162 (7) : 1351-1360.
 
13) Thase ME, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression : A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006 ; 26 (6) : 600-609.
 
14) Thase ME, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression : Results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008 ; 28 (1) : 13-20.
PubMed
15) Gijsman HJ, et al. Antidepressants for bipolar depression : A systematic review of randomized, controlled trials. Am J Psychiatry 2004 ; 161 (9) : 1537-1547.
PubMed
16) Sachs GS, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007 ; 356 (17) : 1711-1722.
PubMed
17) Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder : A randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010 ; 167 (7) : 792-800.
PubMed
18) Derry S, Moore RA. Atypical antipsychotics in bipolar disorder : Systematic review of randomised trials. BMC Psychiatry 2007 ; 7 : 40.
PubMed
19) Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania : A systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007 ; 64 (4) : 442-455.
 
20) Smith LA, et al. Acute bipolar mania : A systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007 ; 115 (1) : 12-20.
 
21) Suppes T, et al. Maintenance treatment for patients with bipolar I disorder : Results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009 ; 166 (4) : 476-488.
PubMed
22) Vieta E, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008 ; 109 (3) : 251-263.
 
23) Schneck CD. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 2006 ; 67 (Suppl 11) : 22-27.
 
24) Ng F, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009 ; 11 (6) : 559-595.
PubMed
25) Colom F, et al. Group psychoeducation for stabilised bipolar disorders : 5-year outcome of a randomised clinical trial. Br J Psychiatry 2009 ; 194 (3) : 260-265.
PubMed
26) Sachs GS, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003 ; 53 (11) : 1028-1042.
PubMed
27) Bauer MS, et al. Collaborative care for bipolar disorder : Part II. Impact on clinical outcome, function, and costs. Psychiatr Serv 2006 ; 57 (7) : 937-945.
PubMed
28) Bauer MS, et al. Collaborative care for bipolar disorder : Part I. Intervention and implementation in a randomized effectiveness trial. Psychiatr Serv 2006 ; 57 (7) : 927-936.
 
29) Miklowitz DJ, et al. Psychosocial treatments for bipolar depression : A 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007 ; 64 (4) : 419-426.
PubMed
30) Yonkers KA, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004 ; 161 (4) : 608-620.
PubMed
31) Yonkers KA, et al. The management of depression during pregnancy : A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol 2009 ; 114 (3) : 703-713.
PubMed
上島国利ほか (編). 気分障害. 東京 : 医学書院 ; 2008.
 
内海健. うつ病新時代-双極II型障害という病. 東京 : 勉誠出版 ; 2006.
 
Goodwin KF, Jamison KR. Manic-Depressive Illness : Bipolar Disorders and Recurrent Depression, 2nd edition. New York : Oxford University Press ; 2007.
 
Akiskal HS, Tohen M. Bipolar Psychopharmacotherapy : Caring for the Patient. West Sussex, England : Wiley ; 2006.
 
Frank E. Treating Bipolar Disorder. A Clinician's Guide to Interpersonal and Social Rhythm Therapy. New York : The Guilford Press ; 2005.
 
Miklowitz DJ. Bipolar Disorder : A Family-Focused Treatment Approach, 2nd edition. New York : The Guilford Press ; 2008.
 
P.158 掲載の参考文献
1) Kleindienst N, Engel RR, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord 2005 ; 7 : 404-417.
PubMed
2) Smith LA, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder : A systematic review of randomized controlled trials. Bipolar Disord 2007 ; 9 : 394-412.
PubMed
3) Fountoulakis KN, Vieta E. Treatment of bipolar disorder : A systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008 ; 11 : 999-1029.
 
4) Schneck CD. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 2006 ; 67 (Suppl 11) : 22-27.
 
5) 寺尾岳. 21世紀のリチウム療法. 東京 : 新興医学出版社 ; 2006.
 
6) 寺尾岳, 和田明彦. 双極性障害の診断・治療と気分安定薬の作用機序. 東京 : 新興医学出版社 ; 2010.
 
P.167 掲載の参考文献
1) 石郷岡純. 双極性障害の大規模臨床試験-Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). 臨床精神薬理 2008 ; 11 : 1275-1283.
 
2) 久住一郎, 小山司. 新たなムードスタビライザー. 臨床精神薬理 2005 ; 8 (3) : 317-323.
 
3) 塩江邦彦. 双極性障害の治療ガイドライン, アルゴリズムからみた抗うつ薬の位置づけ. 臨床精神薬理 2010 ; 13 (8) : 1525-1532.
 
4) Hirschfeld RMA, et al. Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd edition. Washington DC : American Psychiatric Association ; 2002. http://www.psych.org/
 
5) Robert MA, Hirschfeld MD. Guideline Watch : Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd edition. Arlington, VA : American Psychiatric Association ; 2005. pp1-9.
 
6) Keck PE Jr, et al. The Expert Consensus Guidelines : Treatment of Bipolar Disorder 2004. pp1-120.
 
P.176 掲載の参考文献
1) 越野好文. 全般性不安障害. 1. 概念・診断・心理社会的研究. 臨床精神医学 2006 ; 35 (6) : 793-799.
Medical*Online
2) 越野好文. 不安の症状による抗不安薬の使い分け. 今月の治療 2005 ; 13 (8) : 763-769.
 
3) 越野好文. ユビキタスな全般性不安障害. 臨床精神薬理 2005 ; 8 (5) : 757-763.
 
4) 阿部亮, 塩入俊樹. 全般性不安障害. 臨床精神医学 2006 ; 35 (増刊号) : 112-118.
 
5) 川上憲人. こころの健康についての疫学調査に関する研究. 平成16～18年度厚生労働科学研究費補助金 (こころの健康科学研究事業) 「こころの健康についての疫学調査に関する研究」総合研究報告書. 2007. pp1-21.
 
6) 尾鷲登志美. 不安. 下田和孝 (編). 脳とこころのプライマリケア. 1. うつと不安. 東京 : シナジー ; 2006. pp394-416.
 
7) 中込和幸ほか. GAD 研究会が提唱する本邦における『GAD治療手順』. 臨床精神薬理 2008 ; 11 (8) : 1571-1573.
 
8) 越野好文. Benzodiazepine 系抗不安薬 vs. 5-HT1A 受容体部分作動薬 vs. 選択的セロトニン再取り込み阻害薬 vs. 三環系抗うつ薬. 臨床精神薬理 2006 ; 9 (12) : 2413-2420.
 
9) 越野好文. わが国における抗不安薬の使用状況. 精神科 2008 ; 13 (5) : 369-375.
 
10) 越野好文. 抗不安薬開発の歴史. 最新精神医学 2009 ; 14 (6) : 513-518.
 
11) 越野好文. エビデンスの使い方-不安障害. 臨床精神薬理 2003 ; 6 (8) : 1027-1034.
 
12) 越野好文. Sertralineによる不安障害の治療. 臨床精神薬理 2006 ; 9 (9) : 1851-1858.
 
13) 越野好文. 不安障害. 村崎光邦 (編). MR 教育研修テキスト 中枢神経. 東京 : エルゼビア・ジャパン ; 2004. pp105-128.
 
14) McGlynn TJ, et al (eds). Diagnosis and Treatment of Anxiety Disorders : A Physician's Handbook, 2nd ed. Washington DC : American Psychiatric Press ; 1991/越野好文 (訳). 不安障害臨床ハンドブック. 東京 : 金剛出版 ; 1994.
 
保坂 ほか (編). 神経症性障害とストレス関連障害. 精神科臨床ニューアプローチ 3. 東京 : メジカルビュー社 ; 2005.
 
Starcevic V. Anxiety Disorders in Adults : A Clinical Guide. Oxford : Oxford University Press ; 2005.
 
Rapee RM, Barlow DH (eds). Chronic Anxiety : Generalized Anxiety Disorder and Mixed Anxiety-Depression. New York : Guilford ; 1991.
 
Nutt D, Ballenger J (eds). Anxiety Disorders. Oxford : Blackwell ; 2003.
 
笠原嘉. 不安の病理. 東京 : 岩波書店 ; 1981.
 
P.188 掲載の参考文献
1) Neumeister A, et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 2004 ; 24 (3) : 589-591.
PubMed
2) Nash JR, et al. Serotonin 5-HT1A receptor binding in people with panic disorder : Positron emission tomography study. Br J Psychiatry 2008 ; 193 (3) : 229-234.
PubMed
3) Malizia AL, et al. Decreased brain GABA (A) -benzodiazepine receptor binding in panic disorder : Preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998 ; 55 (8) : 715-720.
 
4) Bremner JD, et al. SPECT [I-123] iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 2000 ; 47 (2) : 96-106.
PubMed
5) Cameron OG, et al. Reduced gamma-aminobutyric acid (A) -benzodiazepine binding sites in insular cortex of individuals with panic disorder. Arch Gen Psychiatry 2007 ; 64 (7) : 793-800.
PubMed
6) Hasler G, et al. Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C] flumazenil positron emission tomography. Arch Gen Psychiatry 2008 ; 65 (10) : 1166-1175.
PubMed
7) Roy-Byrne PP, et al. Preliminary evidence of benzodiazepine subsensitivity in panic disorder. Biol Psychiatry 1989 ; 26 (7) : 744-748.
PubMed
8) Roy-Byrne PP, et al. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 1990 ; 47 (6) : 534-538.
PubMed
9) Bruce SE, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? Am J Psychiatry 2003 ; 160 (8) : 1432-1438.
PubMed
10) Mulch G. Comparison of the effectiveness of antivertiginous drugs by double blind procedure. The effect of diazepam, dimenhydrinate and sulpirid on the human vestibular spontaneous nystagmus (author's transl). Laryngol Rhinol Otol (Stuttg) 1976 ; 55 (5) : 392-399. [Article in German]
 
11) Pezze MA, Feldon J. Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol 2004 ; 74 (5) : 301-320.
PubMed
12) Morrow BA, et al. The role of mesoprefrontal dopamine neurons in the acquisition and expression of conditioned fear in the rat. Neuroscience 1999 ; 92 (2) : 553-564.
PubMed
13) Ponnusamy R, Nissim HA, Barad M. Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice. Learn Mem 2005 ; 12 (4) : 399-406.
PubMed
14) del Rosario CN, Pacchioni AM, Cancela LM. Influence of acute or repeated restraint stress on morphine-induced locomotion : Involvement of dopamine, opioid and glutamate receptors. Behav Brain Res 2002 ; 134 (1-2) : 229-238.
PubMed
15) Prosser JM, et al. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks : A randomized, single-blind study. BMC Psychiatry 2009 ; 9 : 25.
PubMed
16) Stahl SM. The 7 habits of highly effective psychopharmacologists : Overview. J Clin Psychiatry 2006 : 61 (4) ; 242-243
 
17) 貝谷久宣. 非定型うつ病-不安障害との併発をめぐって. 精神医学 2010 ; 52 (9) : 840-852.
 
貝谷久宣. 非定型うつ病. 中込和幸 (編). 専門医のための精神科臨床リュミエール 15 難治性精神障害へのストラテジー. 東京 : 中山書店 ; 2010. pp63-75.
 
American Psychiatric Association. Practice Guideline for the Treatment of Patients with Panic Disorder, 2nd edition. Am J Psychiatry 2009 ; 166 (Suppl 2) : 7.
 
熊野宏昭ほか (編). パニック障害ハンドブック-治療ガイドラインと診療の実際. 東京 : 医学書院 ; 2008.
 
貝谷久宣ほか (編). 非定型うつ病. 東京 : 日本評論社 ; 2008.
 
P.196 掲載の参考文献
1) 松永寿人. 強迫性障害の疫学と治療. 精神療法 2009 ; 35 (6) : 701-711.
 
2) Goodman WK, et al. The Yale-Brown Obsessive Compulsive Scale, I : Development, use, and reliability. Arch Gen Psychiatry 1989 ; 46 : 1006-1011.
PubMed
3) Goodman WK, et al. The Yale-Brown Obsessive Compulsive Scale, II : Validity. Arch Gen Psychiatry 1989 ; 46 : 1012-1016.
PubMed
4) Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am 2006 ; 29 : 553-584.
PubMed
5) Koran LM, et al. Practice guideline for the treatment of patients with obsessivecompulsive disorder. Am J Psychiatry 2007 ; 164 (7 Suppl) : 1-56.
 
6) Skapinakis P, Papatheodorous T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder : A meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007 ; 17 : 79-93.
 
March JS, et al. Expert consensus guidelines : Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997 ; 58 (Suppl 4) : 1-72. / 大野裕 (訳). エキスパートコンセンサスガイドライン-強迫性障害 (OCD) の治療. 東京 : ライフサイエンス社 ; 1999.
 
松永寿人. 強迫性障害に対する現在の薬物療法-その実際と効果予測. 臨床精神薬理 2009 ; 12 (9) : 1923-1932.
 
Matsunaga H, et al. A long-term trial on the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry 2009 ; 70 (6) : 863-868.
PubMed
Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder : Methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 2006 ; 30 : 400-412.
PubMed
Westenberg HGM, Fineberg NA, Denys D. Neurobiology of obsessive-compulsive disorder : Serotonin and beyond. CNS Spectr 2007 ; 12 (Suppl 3) : 14-27.
 
松永寿人. いわゆる治療抵抗性とその対応. 上島国利ほか (編). エキスパートによる強迫性障害 (OCD) 治療ブック. 東京 : 星和書店 ; 2010. pp147-162.
 
松永寿人. 強迫性障害の生物学的側面. Bulletin of Depression and Anxiety Disorders 2005 ; 3 (2) : 8-12.
 
中尾智博. 強迫性障害の脳機能と薬物療法の効果. 臨床精神薬理 2009 ; 12 (9) : 1915-1922.
 
Stein DJ, et al. Treatment of obsessive-compulsive disorder. CNS Spectr 2007 ; 12 (2 Suppl 3) : 28-35.
 
多賀千明, 松永寿人, 宍倉久理江. 強迫性障害の症候学的特徴と疫学. 上島国利ほか (編). エキスパートによる強迫性障害 (OCD) 治療ブック. 東京 : 星和書店 ; 2010. pp9-20.
 
渡邉昌祐. SSRIのプロファイルの違いとその使い分け. 臨床精神薬理 2007 ; 10 : 295-307.
 
P.206 掲載の参考文献
1) 永田利彦. 社交不安障害の概念. 精神科 2010 ; 17 : 105-110.
 
2) Marks IM, Gelder MG. Different ages of onset in varieties of phobia. Am J Psychiatry 1966 ; 123 : 218-221.
PubMed
3) Liebowitz MR, et al. Social phobia. Review of a neglected anxiety disorder. Arch Gen Psychiatry 1985 ; 42 : 729-736.
PubMed
4) Bogels SM, et al. Social anxiety disorder : Questions and answers for the DSM-V. Depress Anxiety 2010 ; 27 : 168-189.
PubMed
5) Heimberg RG, et al. Trends in the prevalence of social phobia in the United States : A synthetic cohort analysis of changes over four decades. Eur Psychiatry 2000 ; 15 : 29-37.
PubMed
6) Stein DJ, et al. Subtyping social anxiety disorder in developed and developing countries. Depress Anxiety 2010 ; 27 : 390-403.
PubMed
7) Zimmerman M, Chelminski I. Clinician recognition of anxiety disorders in depressed outpatients. J Psychiatr Res 2003 ; 37 : 325-333.
PubMed
8) 永田利彦ほか. ひきこもる摂食障害を就労支援へつなげることのできた2症例. 精神医学 2010 ; 52 : 17-24.
 
9) Kagan J, Reznick JS, Snidman N. Biological bases of childhood shyness. Science 1988 ; 240 : 167-171.
PubMed
10) Stein MB, Stein DJ. Social anxiety disorder. Lancet 2008 ; 371 : 1115-1125.
PubMed
11) 永田利彦ほか. 社会不安障害に対する薬物療法-古典的対人恐怖, ひきこもりとの関連. 精神医学 2004 ; 46 : 933-939.
 
12) Blanco C, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010 ; 67 : 286-295.
 
Bandelow B, et al (eds). Social Anxiety Disorder. New York : Marcel Dekker ; 2004.
 
P.214 掲載の参考文献
1) Lader MH, Petursson H. Benzodiazepine derivatives : Side effect and dangers. Biol Psychiatry 1981 ; 16 : 1195-1201.
PubMed
2) 井澤志名野, 早川達郎, 和田清. ベンゾジアゼピン系薬物の使用原則と臨床用量依存の診断と治療. 白倉克之ほか (編). アルコール・薬物関連障害の診断・治療ガイドライン. 東京 : じほう ; 2003. pp207-222.
 
3) Rickels K, et al. Long-term diazepam therapy and clinical outcome. JAMA 1983 ; 250 : 767-771.
PubMed
4) Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals-implications for long-term use and abuse. Psychopharmacology (Berl) 1997 ; 134 : 11-37.
 
5) 早川達郎ほか. ベンゾジアゼピン系薬物の精神機能への影響に関する研究. 厚生労働省精神・神経疾患研究委託費「精神作用物質性精神障害の脳内機序並びに診断・治療に関する研究」, 平成10年度研究報告書. 1999. pp95-103.
 
6) Golombok S, Moodley P, Lader M. Cognitive improvement in longterm benzodiazepine users. Psychol Med 1988 ; 18 : 365-374.
 
7) 村崎光邦ほか. ベンゾジアゼピン系薬物常用量依存について-その3 : ベンゾジアゼピン系薬物長期服用者の精神運動機能の研究. 厚生労働省精神・神経疾患研究委託費「薬物依存の発生機序と臨床および治療に関する研究」, 平成4年度研究成果報告書. 1993. pp155-162.
 
8) Ray WA, Fought RL, Decker MD. Psychoactive drugs and risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992 ; 136 : 873-883.
PubMed
9) Fyer AJ, et al. Discontinuation of alprazolam treatment in panic patient. Am J Psychiatry 1987 ; 144 : 303-308.
PubMed
10) The Royal College of Psychiatrists. CR59. Benzodiazepines : Risks, Benefits and Dependence : A Re-evaluation. Council Report CR59 January 1997. London : Royal College of Psychiatrists ; 1997.
 
11) 藤井康男. Nitrazepamを分裂病者に連用するのは適当か. 精神神経誌 1982 ; 84 : 162-183.
 
12) 村崎光邦. わが国における向精神薬の現状と展望-21世紀をめざして. 臨床精神薬理 2001 ; 4 : 3-27.
 
13) 田島治. ベンゾジアゼピン系薬物の処方を再考する. 臨床精神医学 2001 ; 30 : 1065-1069.
Medical*Online
14) 村崎光邦ほか. ベンゾジアゼピン系薬物常用量依存について-その1 : 北里大学東病院精神神経科外来における実態調査. 厚生労働省精神・神経疾患研究委託費「薬物依存の発生機序と臨床および治療に関する研究」, 平成2年度研究成果報告書. 1991. pp13-19.
 
15) 尾崎茂, 和田清, 大槻直美. 全国の精神科医療施設における薬物関連障害の実態調査. 平成20年度厚生労働科学研究費補助金 医薬品・医療機器等レギュラトリーサイエンス総合事業「薬物乱用・依存等の実態把握と「回復」に向けての対応策に関する研究」. 2009. pp87-134.
 
16) O'brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005 ; 66 (Suppl 2) : 28-33.
 
17) 村崎光邦ほか. ベンゾジアゼピン系薬物長期服用者の治療について-長期服用者のQOL評価の変遷と5-HT 1A 受容体作動性抗不安薬を用いた治療について. 厚生労働省精神・神経疾患研究委託費「精神作用物質性精神障害の脳内機序並びに診断・治療に関する研究」, 平成10年度研究報告書. 1999. pp105-111.
 
18) Schweizer E, et al. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients. Psychol Med 1998 ; 28 : 713-720.
PubMed

III 薬物治療と他の治療法との比較

P.222 掲載の参考文献
1) APA. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington DC : American Psychiatric Association ; 1994.
 
2) Kessler RC, et al. The epidemiology of major depressive disorder : Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 ; 289 : 3095-3105.
PubMed
3) Demyttenaere K, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004 ; 291 : 2581-2590.
PubMed
4) APA. Practice guideline for the treatment of patients with major depressive disorder. Washington DC : American Psychiatric Association ; 2004.
 
5) NICE. Depression : The Treatment and Management of Depression in Adults, Clinical Guideline 90. London : National Institute for Clinical Excellence ; 2009.
 
6) Gloaguen V, et al. A meta-analysis of the effects of cognitive therapy in depressed patients. J Affect Disord 1998 ; 49 : 59-72.
PubMed
7) Wampold BE, et al. A meta- (re) analysis of the effects of cognitive therapy versus' other therapies' for depression. J Affect Disord 2002 ; 68 : 159-165.
PubMed
8) Kessler D, et al. Therapist-delivered Internet psychotherapy for depression in primary care : A randomised controlled trial. Lancet 2009 ; 374 : 628-634.
PubMed
9) Hollon SD, et al. Cognitive therapy and pharmacotherapy for depression. Singly and in combination. Arch Gen Psychiatry 1992 ; 49 : 774-781.
PubMed
10) DeRubeis RJ, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005 ; 62 : 409-416.
PubMed
11) Cuijpers P, et al. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry 2008 ; 69 : 1675-1685.
PubMed
12) Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions : A meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry 2006 ; 163 : 1493-1501.
PubMed
13) Thase ME, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997 ; 54 : 1009-1015.
 
14) Elkin I, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989 ; 46 : 971-982 ; discussion 983.
PubMed
15) Cuijpers P, et al. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression : A meta-analysis. Depress Anxiety 2009 ; 26 ; 279-288.
PubMed
16) Pampallona S, et al. Combined pharmacotherapy and psychological treatment for depression : A systematic review. Arch Gen Psychiatry 2004 ; 61 : 714-719.
PubMed
17) Keller MB, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000 ; 342 : 1462-1470.
PubMed
18) March J, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression : Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004 ; 292 : 807-820.
PubMed
19) TADS team, et al. The Treatment for Adolescents With Depression Study (TADS) : Outcomes over 1 year of naturalistic follow-up. Am J Psychiatry 2009 ; 166 : 1141-1149.
 
20) Cuijpers P, et al. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults : A meta-analysis. J Clin Psychiatry 2009 ; 70 : 1219-1229.
PubMed
21) Hollon SD, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005 ; 62 : 417-422.
PubMed
22) Fava GA, et al. Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998 ; 155 : 1443-1445.
PubMed
23) Fava GA, et al. Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1996 ; 153 : 945-947.
PubMed
24) Fava GA, et al. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994 ; 151 : 1295-1299.
PubMed
25) Fava GA, et al. Prevention of recurrent depression with cognitive behavioral therapy : Preliminary findings. Arch Gen Psychiatry 1998 ; 55 : 816-820.
PubMed
26) Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. J Consult Clin Psychol 2008 ; 76 : 468-477.
PubMed
27) de Mello MF, et al. A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. Eur Arch Psychiatry Clin Neurosci 2005 ; 255 : 75-82.
PubMed
28) Barber JP, Muenz LR. The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy : Empirical findings from the treatment for depression collaborative research program. J Consult Clin Psychol 1996 ; 64 : 951-958.
PubMed
29) Shea MT, et al. Personality disorders and treatment outcome in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 1990 ; 147 : 711-718.
PubMed
30) Reynolds CF 3rd, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression : A randomized controlled trial in patients older than 59 years. JAMA 1999 ; 281 : 39-45.
PubMed
31) Frank E, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990 ; 47 : 1093-1099.
PubMed
32) Reynolds CF 3rd, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006 ; 354 : 1130-1138.
PubMed
P.228 掲載の参考文献
1) Janicak PG, et al. Efficacy of ECT : A meta-analysis. Am J Psychiatry 1985 ; 142 : 297-302.
PubMed
2) UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders : A systematic review and meta-analysis. Lancet 2003 ; 361 : 799-808.
PubMed
3) Kho KH, et al. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT 2003 ; 19 : 139-147.
 
4) Pagnin D, et al. Efficacy of ECT in depression : A meta-analytic review. J ECT 2004 ; 20 : 13-20.
PubMed
5) 本橋伸高. 難治性うつ病に対する非薬物療法の展望-生物学的側面. 臨床精神薬理 2009 ; 12 : 859-865.
 
6) McIntosh AM, Lawrie SM. Systematic review of psychotropic medication given during a course of ECT for depressive illness : Therapeutic and adverse consequences. In : Scott AIF (ed). The ECT Handbook : The Third Report of the Royal College of Psychiatrists' Special Committee on ECT. London : Royal College of Psychiatrists ; 2005. pp85-98.
 
7) Baghai TC, et al. The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry 2006 ; 7 : 82-90.
PubMed
8) Sackeim HA, et al. Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes : Short-term efficacy and adverse effects. Arch Gen Psychiatry 2009 ; 66 : 729-737.
PubMed
9) Loo CK, et al. The difficult-to-treat electroconvulsive therapy patient-Strategies for augmenting outcomes. J Affect Disord 2010 ; 124 : 219-227.
PubMed
10) Rasmussen KG, et al. Is baseline medication resistance associated with potential for relapse after successful remission of a depressive episode with ECT? Data from the Consortium for Research on Electroconvulsive Therapy (CORE). J Clin Psychiatry 2009 ; 70 : 232-237.
 
11) McIntosh AM, Lawrie SM. Systematic review. Continuation pharmacotherapy after ECT for depressive illness. In : Scott AIF (ed). The ECT Handbook : The Third Report of the Royal College of Psychiatrists' Special Committee on ECT. London : Royal College of Psychiatrists ; 2005. pp99-108.
 
12) Sackeim HA, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy : A randomized controlled trial. JAMA 2001 ; 285 : 1299-1307.
PubMed
13) Kellner CH, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression : A multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006 ; 63 : 1337-1344.
 
14) Trevino K, McClintock SM, Husain MM. A review of continuation electroconvulsive therapy : Application, safety, and efficacy. J ECT 2010 ; 26 : 186-195.
PubMed
15) 本橋伸高. 電気けいれん療法. 精神科薬物療法研究会 (編). 気分障害の薬物治療アルゴリズム. 東京 : じほう ; 2003. pp141-148.
 
Abrams R. Electroconvulsive Therapy, 4th edition. New York : Oxford University Press ; 2002. / 一瀬邦弘ほか (監訳). 電気けいれん療法. 東京 : へるす出版 ; 2005.
 
American Psychiatric Association Committee on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy : Recommendations for Treatment, Training, and Privileging, 2nd edition. Washington DC : American Psychiatric Association ; 2001. / 日本精神神経学会電気けいれん療法の手技と適応基準の検討小委員会 (監訳). 米国精神医学会タスクフォースレポートECT実践ガイド. 東京 : 医学書院 ; 2002.
 
Mankad MV, et al. Clinical Manual of Electroconvulsive Therapy. Arlington : American Psychiatric Publishing, Inc ; 2009.
 
Scott AIF (ed). The ECT Handbook : The Third Report of the Royal College of Psychiatrists' Special Committee on ECT. London : Royal College of Psychiatrists ; 2005.
 
P.237 掲載の参考文献
1) 越野好文. SSRI, SNRIの登場で不安障害治療ストラテジーがどう変化したか? 臨床精神薬理 2008 : 11 (1) ; 61-67.
 
2) Cohn LG, Hope DA. Psychosocial treatments of social phobia : A treatments by dimensions review. In : Hofmann SG, et al (eds). From Social Anxiety to Social Phobia : Multiple Perspectives. Needham Heights, MA : Allyn & Bacon ; 2001. pp354-378.
 
3) Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders : A meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008 ; 69 (4) : 621-632.
PubMed
4) Nathan PE, Gorman JM. A Guide to Treatments that Work, 3rd edition. USA : Oxford University Press ; 2007.
 
5) Wright JH, Basco MR, Thase ME. Learning Cognitive-Behavior Therapy : An Illustrated Guide. Washington DC : American Psychiatric Publishing, Inc. ; 2006.
 
6) Hindmarch I. The behavioural toxicity of antidepressants : Effects on cognition and sexual function. Int Clin Psychopharmacol 1998 ; Suppl 6 : S5-8.
 
7) Bakker A, et al. Cognitive therapy by allocation versus cognitive therapy by preference in the treatment of panic disorder. Psychother Psychosom 2000 ; 69 (5) : 240-243.
PubMed
8) Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia : Systematic review. Br J Psychiatry 2006 ; 188 : 305-312.
 
9) Watanabe N, Churchill R, Furukawa TA. Combined psychotherapy plus benzodiazepines for panic disorder. Cochrane Database Syst Rev 2009 ; (1) CD005335.
PubMed
American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Panic Disorder, 2009, Psychiatry Online. http://www.psychiatryonline.com/pracGuide
 
American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Obsessive-compulsive Disorder, 2007, Psychiatry Online. http://www.psychiatryonline.com/pracGuide
 
P.246 掲載の参考文献
1) 藤井康男ほか (編). デポ剤による精神科治療技法のすべて. 東京 : 星和書店 ; 1995.
 
2) Nesvag R, et al. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 2006 ; 114 (1) : 21-26.
PubMed
3) Gray JA, Roth BL. The pipeline and future of drug development in schizopohrenia. Mol Psychiatry 2007 ; 12 : 904-922.
PubMed
4) 藤井康男 (編). LAIマスターブック. 東京 : アルタ出版 ; 2010.
 
5) Mannaert E, et al. Pharmacokinetic profile of long-acting injectable risperidone at steady-state : Comparison with oral administration. Encephale 2005 ; 31 : 609-615.
PubMed
6) Roberts LW, Geppert CM. Ethical use of long-acting medications in the treatment of severe and persistent mental illnesses. Compr Psychiatry 2004 : 45 (3) ; 161-167.
PubMed
7) 藤井康男. 重大な犯罪を犯した統合失調症患者とデポ剤治療. 臨床精神薬理 2007 : 10 ; 759-771.
 
8) 藤井康男. 患者自身のデポ剤治療受け入れと精神科医の役割. 臨床精神薬理 2009 : 12 ; 1059-1073.
 
9) Patel MX, et al. Are depot antipsychotics more coercive than tablets? The patient's perspective. J Psychopharmacol 2010 ; 24 : 1483-1489.
PubMed
10) Goldbeck R, Tomlinson S, Bouch J. Patients' knowledge and views of their depot neuroleptic medication. Psychiatric Bulletin 1999 : 23 ; 467-470.
 

IV 向精神薬の未来

P.255 掲載の参考文献
1) 高橋明比古. 神経ペプチドの可能性を探る. 臨床精神薬理 2004 ; 7 : 1757-1768.
 
2) Karlsson P, et al. Pharmacokinetics dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Poster presented at Winter Workshop on Schizophrenia (WWS) 2006, Davos, Switzerland, 5-11 February, 2006, Poster no. 25.
 
3) Svensson TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003 ; 27 : 1145-1158.
PubMed
4) Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia : A placebo- and risperidone-controlled trial. J Clin Psychiatry 2007 ; 68 : 1492-1500.
 
5) Van Vliet BJ, et al. DU 127090 : A highly potent, atypical dopamine receptor ligand? A putative potent full spectrum antipsychotic with low EPS potential. Eur Neuropsychopharmacol 2000 ; 10 (Suppl3) : 293.
 
6) Freedman R, et al. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995 ; 38 : 22-33.
PubMed
7) Martin LF, Kem WR, Freedman R. α7 Nicotinic receptor agonists : Potential new candidates for the treatment of schizophrenia. Psychopharmacology 2004 ; 74 : 54-64.
 
8) Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors : Native subtypes and their relevance. Trends Pharmacol Sci 2006 ; 27 : 482-491.
PubMed
9) Goff DC, Freudenreich O, Evins AE. Augmentation strategies in the treatment of schizophrenia. CNS Spectr 2001 ; 6 : 904, 907-911.
 
10) Frye MA, et al. Placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000 ; 20 (6) : 607-614.
PubMed
11) Calabrese JR, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999 ; 156 (7) : 1019-1023.
PubMed
12) Cabras PL, et al. Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder : Results of an open-label study. J Clin Psychiatry 1999 ; 60 (4) : 245-248.
PubMed
13) Pande AC, et al. Gabapentin in bipolar disorder : A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group.Bipolar Disord 2000 ; 2 (3 Pt 2) : 249-255.
 
14) McIntyre RS, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder : A preliminary single-blind study. Bipolar Disord 2002 ; 4 : 207-213.
PubMed
15) McElroy SL, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000 ; 47 : 1025-1033.
PubMed
16) Skolnock P, Basile AS. Triple reuptake inhibitors ("broad spectrum" antidepressants). CNS Neurol Disord Drug Targets 2007 ; 6 : 141-149.
 
17) Skolnick P, et al. "Broad spectrum" antidepressants : Is more better for the treatment of depression? Life Sci 2003 ; 73 : 3175-3179.
PubMed
18) Skolnick P, et al. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev 2006 ; 12 : 123-134.
PubMed
19) Shaw AM, et al. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur J Pharmacol 2007 ; 555 : 30-36.
PubMed
20) Kinney GG, Taber MT, Gribkoff VK. The augmentation hypothesis for improvement of antidepressant therapy : Is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Mol Neurobiol 2000 ; 21 : 137-152.
PubMed
21) Nisoli E, et al. Rat frontal cortex beta 1-adrenoceptors are activated by the beta 3-adrenoceptor agonists SR 58611A and SR 58878A but not by BRL 37344 or ICI 215,001. J Neurochem 1995 ; 65 : 1580-1587.
PubMed
22) Giardina GA, Gagliardi S, Martinelli M. Antagonists at the neurokinin receptors--recent patent literature. IDrugs 2003 ; 6 : 758-772.
PubMed

書評

最近チェックした商品履歴

Loading...